This CPB has been revised to state that the following are considered experimental and investigational: (i) recombinant factor VIIa for the treatment of diffuse alveolar hemorrhage, gastro-intestinal bleeding after hematopoietic stem cell transplantation, and hemoptysis due to invasive pulmonary aspergillosis; and (ii) human anti-thrombin III for recurrent early miscarriage. Additional brand names of clotting factors were added to the policy.